COVID-19 vaccination in Norway

Last updated

COVID-19 vaccination in Norway
Date27 December 2020 (2020-12-27) – present
Location Norway
Cause COVID-19 pandemic in Norway

COVID-19 vaccination in Norway is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. 870,524 people had been vaccinated with the first dose and 296,458 fully vaccinated as of 17 April 2021; mostly elderly people, healthcare workers and younger people at risk.

In May 2021, an expert review commissioned by the Norwegian Medicines Agency to investigate "the cause of the first 100 reported deaths of nursing home residents who had received the Pfizer-BioNTech vaccine" concluded that "a causal link between the Pfizer-BioNTech vaccine and death was considered “likely” in 10 of the 100 cases, “possible” in 26 cases, and “unlikely” in 59 cases. The remaining five were deemed “unclassifiable.”" [1]

Norway is also closely monitoring side effects, with both reports from healthcare professionals and the public being registered in a common database. This should allow for a good overview of the situation once the vaccine is distributed in the general population, as well as an efficient collaboration with other countries. [2] [3]

Vaccines on order

There are several COVID-19 vaccines at various stages of development around the world.

VaccineApprovalDeployment
Pfizer–BioNTech Green check.svg 21 December 2020Green check.svg 27 December 2020
Moderna Green check.svg 6 January 2021Green check.svg 12 January 2021
Oxford-AstraZeneca Green check.svg 29 January 2021Green check.svg 7 February 2021
Janssen Green check.svg 11 March 2021Green check.svg 5 May 2021
CureVac PendingPending
Novavax PendingPending
Valneva PendingPending
Sanofi–GSK PendingPending

Related Research Articles

COVID-19 vaccine Vaccine designed to provide acquired immunity against SARS-CoV-2

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19). Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). This knowledge accelerated the development of various vaccine platforms during early 2020. The initial focus of SARS-CoV-2 vaccines was on preventing symptomatic, often severe illness. On 10 January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by 19 March, the global pharmaceutical industry announced a major commitment to address COVID-19. The COVID‑19 vaccines are widely credited for their role in reducing the spread, severity, and death caused by COVID-19.

Pfizer–BioNTech COVID-19 vaccine mRNA-based COVID-19 vaccine

The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech and for its development collaborated with American company Pfizer, for support with clinical trials, logistics, and manufacturing. It is authorized for use in people aged twelve years and older in some jurisdictions and for people sixteen years and older in other jurisdictions, to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus. The vaccine is given by intramuscular injection. It is composed of nucleoside-modified mRNA (modRNA) encoding a mutated form of the full-length spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles. Initial advice indicated that vaccination required two doses given 21 days apart, but the interval was later extended to up to 42 days in the US, and up to four months in Canada.

COVID-19 vaccination in the United Kingdom Immunisation against COVID-19

The COVID-19 vaccination programme in the United Kingdom is an ongoing mass immunisation campaign for coronavirus disease 2019 (COVID-19) during the COVID-19 pandemic in the United Kingdom. The UK's vaccination rollout was the world's first mass immunisation programme for the disease when it began on 8 December 2020 after Margaret Keenan received her first dose of two. As of 6 October 2021, 49,068,705 first doses and 45,078,529 second doses of a vaccine had been administered across the UK.

COVID-19 vaccination in Switzerland Plan to immunize against COVID-19

COVID-19 vaccination in Switzerland is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Italy

The COVID-19 vaccination campaign in Italy is a mass immunization campaign that was put in place by the Italian government in order to respond to the ongoing COVID-19 pandemic. It started on 27 December 2020, together with most countries in the European Union.

COVID-19 vaccination in Israel

Israel's COVID-19 vaccination programme, officially named "Give a Shoulder", began on 19 December 2020, and has been praised for its speed, having given twenty percent of the Israeli population the first dose of the vaccines' two dose regimen in the span of three weeks.

COVID-19 vaccination in India Immunisation programme against COVID-19 in India

India began administration of COVID-19 vaccines on 16 January 2021. As of 16 October 2021, India has administered over 976 million doses overall, including first and second doses of the currently-approved vaccines. In India, nearly half the eligible population has got at least one shot, and 19 per cent received both nine months after the vaccine rollout.

Deployment of COVID-19 vaccines Distribution and administration of COVID-19 vaccinations

As of 15 October 2021 6.64 billion COVID-19 vaccine doses had been administered worldwide, with 47.4 per cent of the global population having received at least one dose. While 21.41 million vaccines were then being administered daily, only 2.7 per cent of people in low-income countries had received at least a first vaccine by October 2021, according to official reports from national health agencies, which is collated by Our World in Data.

COVID-19 vaccination in Australia Ongoing COVID-19 vaccine program in Australia

The general COVID-19 vaccination in Australia program began on 22 February 2021 in response to the COVID-19 pandemic, and will continue with the goal of vaccinating all willing Australians before 2022. Front-line workers and aged care staff and residents will be the first Australians to be inoculated, before a gradual phased release to less-vulnerable and lower-risk population groups throughout 2021. The Therapeutic Goods Administration (TGA) approved four vaccines for Australian use in 2021: the Pfizer–BioNTech vaccine on 25 January, the Oxford–AstraZeneca vaccine on 16 February, Janssen vaccine on 25 June and the Moderna vaccine on 9 August. Although approved for use, the Janssen vaccine is not included in the Australian vaccination program.

COVID-19 vaccination in South Africa Plan to immunize against COVID-19 in South Africa

COVID-19 vaccination in South Africa is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in the United States Plan to immunize against COVID-19

The COVID-19 vaccination campaign in the United States is an ongoing mass immunization campaign for the COVID-19 pandemic in the United States. The Food and Drug Administration (FDA) first granted emergency use authorization to the Pfizer–BioNTech vaccine on December 10, 2020; mass vaccinations began on December 14, 2020. The Moderna vaccine was granted emergency use authorization on December 17, 2020, and the Janssen vaccine was granted emergency use authorization on February 27, 2021. By April 19, 2021, all U.S. states had opened vaccine eligibility to residents aged 16 and over. On May 10, 2021, the FDA approved the Pfizer-BioNTech vaccine for adolescents aged 12 to 15. On August 23, 2021, the FDA granted full approval to the Pfizer–BioNTech vaccine for individuals aged 16 and over.

COVID-19 vaccination in Botswana is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

The COVID-19 vaccination program in Colombia is an ongoing effort of mass immunization put in place by the Colombian government in order to respond to the ongoing COVID-19 pandemic. The COVID-19 virus was confirmed to have reached Colombia on 6 March 2020. Colombia's preparation and readiness for a vaccine program allowed it to join the first group of countries who received vaccines through COVAX. The first vaccine in Colombia was given to a nurse on 17 February 2021.

COVID-19 vaccination in New Zealand Ongoing COVID-19 vaccine programme in New Zealand

COVID-19 vaccination in New Zealand began on 20 February 2021, and will continue throughout the year with the goal of vaccinating all willing New Zealanders aged 12+. As of 1 September, anyone in New Zealand is eligible to be vaccinated.

COVID-19 vaccination in Africa Immunisation programme against COVID-19 in Africa

COVID-19 vaccination programs have begun in many countries and territories in Africa. As of 5 July 2021, vaccination campaigns had started in 51 African countries with 36.5 million people receiving at least one dose.

COVID-19 vaccination in Mexico Plan to immunize against COVID-19

COVID-19 vaccination in Mexico is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in South Korea Plan to immunize against COVID-19

COVID-19 vaccination in South Korea is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Singapore Plan to immunize against COVID-19

COVID-19 vaccination in Singapore is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. As of 14 October 2021, Singapore has administrated a total of 9,563,625 doses under its national vaccination programme.

COVID-19 vaccination in Ukraine

The COVID-19 vaccination campaign in Ukraine is an ongoing mass immunization campaign for the COVID-19 pandemic in Ukraine.

COVID-19 vaccine clinical research

COVID-19 vaccine clinical research is the clinical research on COVID-19 vaccines, including their efficacy, effectiveness and safety. There are 24 vaccines authorized for use by national governments, with six vaccines being approved for emergency or full use by at least one WHO-recognised stringent regulatory authority; and five of them are in Phase IV. 204 vaccines under clinical trials that have not yet been authorized. There are also nine clinical trials on heterologous vaccination courses.

References

  1. Torjesen, Ingrid (May 27, 2021). "Covid-19: Pfizer-BioNTech vaccine is "likely" responsible for deaths of some elderly patients, Norwegian review finds". BMJ. 373: n1372. doi:10.1136/bmj.n1372. ISSN   1756-1833. PMID   34045236. S2CID   235204094.
  2. "International interest about deaths following coronavirus vaccination". Norwegian Institute of Public Health.
  3. "Reported suspected adverse reactions of covid-19 vaccines". Statens legemiddelverk.